Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 6
Submit an article Journal homepage
73
Views
15
CrossRef citations to date
0
Altmetric
Reviews

Novel mechanistic concept of platelet inhibition

Alexander B Sigalov Research Assistant Professor University of Massachusetts Medical School, Department of Pathology, 55 Lake Avenue North, Worcester, MA 01655, USA +1 508 8568803; +1 508 8560019; [email protected]
, PhD
Pages 677-692 | Published online: 15 May 2008

Bibliography

  • Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circulation 2005;112(17):2725-34
  • Clemetson KJ. Platelet collagen receptors: a new target for inhibition? Haemostasis 1999;29(1):16-26
  • Jackson SP, Schoenwaelder SM. Antiplatelet therapy: in search of the ‘magic bullet’. Nat Rev Drug Discov 2003;2(10):775-89
  • Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003;102(2):449-61
  • Moroi M, Jung SM. Platelet glycoprotein VI: its structure and function. Thromb Res 2004;114(4):221-33
  • Farndale RW. Collagen-induced platelet activation. Blood Cells Mol Dis 2006;36(2):162-5
  • Farndale RW, Siljander PR, Onley DJ, et al. Collagen-platelet interactions: recognition and signalling. Biochem Soc Symp 2003;70:81-94
  • Farndale RW, Sixma JJ, Barnes MJ, et al. The role of collagen in thrombosis and hemostasis. J Thromb Haemost 2004;2(4):561-73
  • Bhatt DL. Intensifying platelet inhibition – navigating between Scylla and Charybdis. N Engl J Med 2007;357(20):2078-81
  • McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci 2003;93(4):381-96
  • Clemetson KJ, Clemetson JM. Collagen receptors as potential targets for novel anti-platelet agents. Curr Pharm Des 2007;13(26):2673-83
  • Arai M, Yamamoto N, Moroi M, et al. Platelets with 10% of the normal amount of glycoprotein VI have an impaired response to collagen that results in a mild bleeding tendency. Br J Haematol 1995;89(1):124-30
  • Moroi M, Jung SM, Okuma M, et al. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989;84(5):1440-5
  • Kato K, Kanaji T, Russell S, et al. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 2003;102(5):1701-7
  • Poole A, Gibbins JM, Turner M, et al. The Fc receptor γ-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997;16(9):2333-41
  • Nieswandt B, Bergmeier W, Schulte V, et al. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRγ chain. J Biol Chem 2000;275(31):23998-4002
  • Lockyer S, Okuyama K, Begum S, et al. GPVI-deficient mice lack collagen responses and are protected against experimentally induced pulmonary thromboembolism. Thromb Res 2006;118(3):371-80
  • Moroi M, Jung SM, Shinmyozu K, et al. Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion. Blood 1996;88(6):2081-92
  • Penz S, Reininger AJ, Brandl R, et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 2005;19(8):898-909
  • Li H, Lockyer S, Concepcion A, et al. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol 2007;27(5):1199-205
  • Kleinschnitz C, Pozgajova M, Pham M, et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007;115(17):2323-30
  • Lecut C, Feeney LA, Kingsbury G, et al. Human platelet glycoprotein VI function is antagonized by monoclonal antibody-derived Fab fragments. J Thromb Haemost 2003;1(12):2653-62
  • Massberg S, Konrad I, Bultmann A, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 2004;18(2):397-9
  • Gruner S, Prostredna M, Koch M, et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 2005;105(4):1492-9
  • Cosemans JM, Kuijpers MJ, Lecut C, et al. Contribution of platelet glycoprotein VI to the thrombogenic effect of collagens in fibrous atherosclerotic lesions. Atherosclerosis 2005;181(1):19-27
  • Massberg S, Gawaz M, Gruner S, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003;197(1):41-9
  • Chu X, Hou M, Peng J, et al. Identification of human platelet glycoprotein VI-specific IgG autoantibody and its fragments. Blood Coagul Fibrinolysis 2006;17(5):403-7
  • Clemetson KJ, McGregor JL, James E, et al. Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. J Clin Invest 1982;70(2):304-11
  • Nieswandt B, Schulte V, Bergmeier W, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 2001;193(4):459-69
  • Miura Y, Takahashi T, Jung SM, et al. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem 2002;277(48):46197-204
  • Smethurst PA, Onley DJ, Jarvis GE, et al. Structural basis for the platelet-collagen interaction: the smallest motif within collagen that recognizes and activates platelet Glycoprotein VI contains two glycine-proline-hydroxyproline triplets. J Biol Chem 2007;282(2):1296-304
  • Horii K, Kahn ML, Herr AB. Structural basis for platelet collagen responses by the immune-type receptor glycoprotein VI. Blood 2006;108(3):936-42
  • Feng J, Garrity D, Call ME, et al. Convergence on a distinctive assembly mechanism by unrelated families of activating immune receptors. Immunity 2005;22(4):427-38
  • George JN. Platelets. Lancet 2000;355(9214):1531-9
  • Bigalke B, Lindemann S, Ehlers R, et al. Expression of platelet collagen receptor glycoprotein VI is associated with acute coronary syndrome. Eur Heart J 2006;27(18):2165-9
  • O'Connor MN, Smethurst PA, Davies LW, et al. Selective blockade of glycoprotein VI clustering on collagen helices. J Biol Chem 2006;281(44):33505-10
  • Calvo E, Tokumasu F, Marinotti O, et al. Aegyptin, a novel mosquito salivary gland protein, specifically binds to collagen and prevents its interaction with platelet glycoprotein VI, integrin α2β1, and von Willebrand factor. J Biol Chem 2007;282(37):26928-38
  • Matsumoto Y, Takizawa H, Gong X, et al. Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization. Thromb Res 2007;119(3):319-29
  • Morita A, Isawa H, Orito Y, et al. Identification and characterization of a collagen-induced platelet aggregation inhibitor, triplatin, from salivary glands of the assassin bug, Triatoma infestans. FEBS J 2006;273(13):2955-62
  • Aiken ML, Ginsberg MH, Byers-Ward V, et al. Effects of OKM5, a monoclonal antibody to glycoprotein IV, on platelet aggregation and thrombospondin surface expression. Blood 1990;76(12):2501-9
  • Busfield SJ, Villeval JL, Jandrot-Perrus M, et al. Glycoprotein VI antibodies and uses thereof. US6989144B1; 2006
  • Schulte V, Reusch HP, Pozgajova M, et al. Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. Arterioscler Thromb Vasc Biol 2006;26(7):1640-7
  • Cauwenberghs N, Vanhoorelbeke K, Vauterin S, et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibα reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibα. Blood 2001;98(3):652-60
  • Hubbard GP, Wolffram S, de Vos R, et al. Ingestion of onion soup high in quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in man: a pilot study. Br J Nutr 2006;96(3):482-8
  • Hubbard GP, Wolffram S, Lovegrove JA, et al. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. J Thromb Haemost 2004;2(12):2138-45
  • Andrews RK, Suzuki-Inoue K, Shen Y, et al. Interaction of calmodulin with the cytoplasmic domain of platelet glycoprotein VI. Blood 2002;99(11):4219-21
  • Suzuki-Inoue K, Tulasne D, Shen Y, et al. Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling. J Biol Chem 2002;277(24):21561-6
  • Locke D, Liu C, Peng X, et al. Fc Rγ-independent signaling by the platelet collagen receptor glycoprotein VI. J Biol Chem 2003;278(17):15441-8
  • Morton LF, Peachey AR, Zijenah LS, et al. Conformation-dependent platelet adhesion to collagen involving integrin α2β1-mediated and other mechanisms: multiple α2β1-recognition sites in collagen type I. Biochem J 1994;299(Pt 3):791-7
  • Zijenah LS and Barnes MJ. Platelet-reactive sites in human collagens I and III: evidence for cell-recognition sites in collagen unrelated to RGD and like sequences. Thromb Res 1990;59(3):553-66
  • Asselin J, Knight CG, Farndale RW, et al. Monomeric (glycine-proline-hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. Biochem J 1999;339(Pt 2):413-8
  • Morton LF, Hargreaves PG, Farndale RW, et al. Integrin α2β1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for α2β1-independent platelet reactivity. Biochem J 1995;306(Pt 2):337-44
  • Kato K, Furihata K, Cheli Y, et al. Effect of multimer size and a natural dimorphism on the binding of convulxin to platelet glycoprotein (GP)VI. J Thromb Haemost 2006;4(5):1107-13
  • Chen H, Locke D, Liu Y, et al. The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion. J Biol Chem 2002;277(4):3011-9
  • Berlanga O, Bori-Sanz T, James JR, et al. Glycoprotein VI oligomerization in cell lines and platelets. J Thromb Haemost 2007;5(5):1026-33
  • Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 2004;61(3):498-511
  • Gibbins JM, Okuma M, Farndale R, et al. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor γ-chain. FEBS Lett 1997;413(2):255-9
  • Sigalov A. Multi-chain immune recognition receptors: spatial organization and signal transduction. Semin Immunol 2005;17(1):51-64
  • Sigalov AB. Multichain immune recognition receptor signaling: different players, same game? Trends Immunol 2004;25(11):583-9
  • Sigalov AB. Immune cell signaling: a novel mechanistic model reveals new therapeutic targets. Trends Pharmacol Sci 2006;27(10):518-24
  • Sigalov AB. Transmembrane interactions as immunotherapeutic targets: lessons from viral pathogenesis. Adv Exp Med Biol 2007;601:335-44
  • Sigalov AB. Signaling chain homooligomerization (SCHOOL) model. In: Sigalov AB, editor, Multichain immune recognition receptor signaling: from spatiotemporal organization to human disease. Austin: Landes Bioscience; 2008:121-63
  • Sigalov AB. SCHOOL model and new targeting strategies. In: Sigalov AB, editor, Multichain immune recognition receptor signaling: from spatiotemporal organization to human disease. Austin: Landes Bioscience; 2008:268-311
  • Sigalov A, Aivazian D, Stern L. Homooligomerization of the cytoplasmic domain of the T cell receptor ζ chain and of other proteins containing the immunoreceptor tyrosine-based activation motif. Biochemistry 2004;43(7):2049-61
  • Sigalov AB, Zhuravleva AV, Orekhov VY. Binding of intrinsically disordered proteins is not necessarily accompanied by a structural transition to a folded form. Biochimie 2007;89(3):419-21
  • Jones S, Thornton JM. Principles of protein–protein interactions. Proc Natl Acad Sci USA 1996;93(1):13-20
  • Kim WM, Sigalov AB. Viral pathogenesis, modulation of immune receptor signaling, and treatment. In: Sigalov AB, editor, Multichain immune recognition receptor signaling: from spatiotemporal organization to human disease. Austin: Landes Bioscience; 2008:325-49
  • Sigalov AB. Inhibiting collagen-induced platelet aggregation and activation with peptide variants. US 12/001,258 and PCT PCT/US2007/025389 patent applications filed on 12/11/2007 and 12/12/2007, respectively, claiming a priority to US 60/874,694 provisional patent application filed on 12/13/2006
  • Sigalov AB. More on: glycoprotein VI oligomerization: a novel concept of platelet inhibition. J Thromb Haemost 2007;5(11):2310-2
  • Rabie T, Varga-Szabo D, Bender M, et al. Diverging signaling events control the pathway of GPVI down-regulation in vivo. Blood 2007;110(2):529-35
  • Schamel WW, Arechaga I, Risueno RM, et al. Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response. J Exp Med 2005;202(4):493-503
  • Davis MM, Boniface JJ, Reich Z, et al. Ligand recognition by αβ T cell receptors. Ann Rev Immunol 1998;16:523-44
  • Sigalov AB, Aivazian DA, Uversky VN, et al. Lipid-binding activity of intrinsically unstructured cytoplasmic domains of multichain immune recognition receptor signaling subunits. Biochemistry 2006;45(51):15731-9
  • Fletcher S, Hamilton AD. Targeting protein–protein interactions by rational design: mimicry of protein surfaces. J R Soc Interface 2006;3(7):215-33
  • Fry DC. Protein–protein interactions as targets for small molecule drug discovery. Biopolymers 2006;84(6):535-52
  • Fry DC, Vassilev LT. Targeting protein–protein interactions for cancer therapy. J Mol Med 2005;83(12):955-63
  • Ryan DP, Matthews JM. Protein–protein interactions in human disease. Curr Opin Struct Biol 2005;15(4):441-6
  • Toogood PL. Inhibition of protein–protein association by small molecules: approaches and progress. J Med Chem 2002;45(8):1543-58
  • Hershberger SJ, Lee SG, Chmielewski J. Scaffolds for blocking protein–protein interactions. Curr Top Med Chem 2007;7(10):928-42
  • Loregian A, Palu G. Disruption of protein–protein interactions: towards new targets for chemotherapy. J Cell Physiol 2005;204(3):750-62
  • Sillerud LO, Larson RS. Design and structure of peptide and peptidomimetic antagonists of protein–protein interaction. Curr Protein Pept Sci 2005;6(2):151-69
  • Archakov AI, Govorun VM, Dubanov AV, et al. Protein–protein interactions as a target for drugs in proteomics. Proteomics 2003;3(4):380-91
  • Berg T. Modulation of protein–protein interactions with small organic molecules. Angew Chem Int Ed Engl 2003;42(22):2462-81
  • Che Y, Brooks BR, Marshall GR. Development of small molecules designed to modulate protein–protein interactions. J Comput Aided Mol Des 2006;20(2):109-30
  • Veselovsky AV, Ivanov YD, Ivanov AS, et al. Protein–protein interactions: mechanisms and modification by drugs. J Mol Recognit 2002;15(6):405-22
  • Pagliaro L, Felding J, Audouze K, et al. Emerging classes of protein–protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol 2004;8(4):442-9
  • Yin H, Slusky JS, Berger BW, et al. Computational design of peptides that target transmembrane helices. Science 2007;315(5820):1817-22
  • Sigalov AB. Interaction between HIV gp41 fusion peptide and T cell receptor: putting the puzzle pieces back together. FASEB J 2007;21(8):1633-4
  • Collins B, Hollidge C. Antithrombotic drug market. Nat Rev Drug Discov 2003;2(1):11-2
  • Arkin M. Protein–protein interactions and cancer: small molecules going in for the kill. Curr Opin Chem Biol 2005;9(3):317-24
  • Bose M, Gestwicki JE, Devasthali V, et al. ‘Nature-inspired’ drug-protein complexes as inhibitors of Aβ aggregation. Biochem Soc Trans 2005;33(Pt 4):543-7
  • Stockwell BR. Exploring biology with small organic molecules. Nature 2004;432(7019):846-84
  • Stoevesandt O, Elbs M, Kohler K, et al. Peptide microarrays for the detection of molecular interactions in cellular signal transduction. Proteomics 2005;5(8):2010-7
  • Watt PM. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat Biotechnol 2006;24(2):177-83
  • Uversky VN, Gillespie JR, Fink AL. Why are “natively unfolded” proteins unstructured under physiologic conditions? Proteins 2000;41(3):415-27
  • Dunker AK, Brown CJ, Lawson JD, et al. Intrinsic disorder and protein function. Biochemistry 2002;41(21):6573-82
  • Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 2005;6(3):197-208
  • Iakoucheva LM, Brown CJ, Lawson JD, et al. Intrinsic disorder in cell-signaling and cancer-associated proteins. J Mol Biol 2002;323(3):573-84
  • Minezaki Y, Homma K, Nishikawa K. Intrinsically disordered regions of human plasma membrane proteins preferentially occur in the cytoplasmic segment. J Mol Biol 2007;368(3):902-13
  • Iakoucheva LM, Radivojac P, Brown CJ, et al. The importance of intrinsic disorder for protein phosphorylation. Nucleic Acids Res 2004;32(3):1037-49
  • Gollner GP, Muller G, Alt R, et al. Therapeutic application of T cell receptor mimic peptides or cDNA in the treatment of T cell-mediated skin diseases. Gene Ther 2000;7(12):1000-4
  • Manolios N, Collier S, Taylor J, et al. T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease. Nat Med 1997;3(1):84-8
  • Manolios N, Huynh NT, Collier S. Peptides in the treatment of inflammatory skin disease. Australas J Dermatol 2002;43(3):226-7
  • Amon MA, Ali M, Bender V, et al. Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function. Biochim Biophys Acta 2006;1763(8):879-88
  • Melnyk RA, Partridge AW, Yip J, et al. Polar residue tagging of transmembrane peptides. Biopolymers 2003;71(6):675-85
  • Cunningham F, Deber CM. Optimizing synthesis and expression of transmembrane peptides and proteins. Methods 2007;41(4):370-80
  • Apic G, Russell RB. A shortcut to peptides to modulate platelets. Nat Chem Biol 2007;3(2):83-4
  • Ashish, Wimley WC. Visual detection of specific, native interactions between soluble and microbead-tethered α-helices from membrane proteins. Biochemistry 2001;40(46):13753-9
  • Edwards RJ, Moran N, Devocelle M, et al. Bioinformatic discovery of novel bioactive peptides. Nat Chem Biol 2007;3(2):108-12
  • Wimley WC, White SH. Designing transmembrane α-helices that insert spontaneously. Biochemistry 2000;39(15):4432-42
  • Killian JA. Synthetic peptides as models for intrinsic membrane proteins. FEBS Lett 2003;555(1):134-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.